Savara says enrollment has been terminated in phase 3 avail and phase 2a encore studies

Savara inc - enrollment has been terminated in phase 3 avail and phase 2a encore studies.savara inc - top line results from avail study are still expected in early 2021.savara inc - has not experienced disruptions to planning of second phase 3 study of molgradex for apap.savara inc - continues conversations with fda regarding study design and endpoints for second phase 3 study of molgradex for apap.savara inc - has not had any supply chain or manufacturing disruptions due to current covid-19 pandemic.
SVRA Ratings Summary
SVRA Quant Ranking